CavoGene LifeSciences, a biotechnology company, has appointed Daniel Jorgensen, MD, MPH, MBA as its new chief executive officer, it was reported on Tuesday.
With over 22 years of experience in small and large companies, both public and private, including C-level positions over the past nine years, Dr Jorgensen has accrued comprehensive research, development, and commercialisation experience for small molecules, biologics/vaccines, and devices, across multiple therapeutic areas, particularly infectious diseases, immunology/inflammation, and rare genetic disorders, playing a main role in multiple regulatory approvals.
Dr Jorgensen holds a BS degree from Yale, MD from University of Wisconsin, MPH from University of Washington and MBA from Yale and holds board certifications in Paediatrics, Infectious Diseases, and Preventive Medicine.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business